279 related articles for article (PubMed ID: 29084745)
1.
Hackel MA; Lomovskaya O; Dudley MN; Karlowsky JA; Sahm DF
Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29084745
[TBL] [Abstract][Full Text] [Related]
2. Effect of the β-Lactamase Inhibitor Vaborbactam Combined with Meropenem against Serine Carbapenemase-Producing Enterobacteriaceae.
Castanheira M; Rhomberg PR; Flamm RK; Jones RN
Antimicrob Agents Chemother; 2016 Sep; 60(9):5454-8. PubMed ID: 27381386
[TBL] [Abstract][Full Text] [Related]
3. In vitro activity of meropenem combined with vaborbactam against KPC-producing Enterobacteriaceae in China.
Zhou M; Yang Q; Lomovskaya O; Sun D; Kudinha T; Xu Z; Zhang G; Chen X; Xu Y
J Antimicrob Chemother; 2018 Oct; 73(10):2789-2796. PubMed ID: 29982437
[TBL] [Abstract][Full Text] [Related]
4. In vitro activity of meropenem/vaborbactam and characterisation of carbapenem resistance mechanisms among carbapenem-resistant Enterobacteriaceae from the 2015 meropenem/vaborbactam surveillance programme.
Pfaller MA; Huband MD; Mendes RE; Flamm RK; Castanheira M
Int J Antimicrob Agents; 2018 Aug; 52(2):144-150. PubMed ID: 29510189
[TBL] [Abstract][Full Text] [Related]
5. Effects of KPC Variant and Porin Genotype on the
Wilson WR; Kline EG; Jones CE; Morder KT; Mettus RT; Doi Y; Nguyen MH; Clancy CJ; Shields RK
Antimicrob Agents Chemother; 2019 Mar; 63(3):. PubMed ID: 30617090
[TBL] [Abstract][Full Text] [Related]
6. Vaborbactam: Spectrum of Beta-Lactamase Inhibition and Impact of Resistance Mechanisms on Activity in Enterobacteriaceae.
Lomovskaya O; Sun D; Rubio-Aparicio D; Nelson K; Tsivkovski R; Griffith DC; Dudley MN
Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28848018
[TBL] [Abstract][Full Text] [Related]
7. Meropenem-Vaborbactam Activity against U.S. Multidrug-Resistant
Shortridge D; Kantro V; Castanheira M
Microbiol Spectr; 2023 Feb; 11(1):e0450722. PubMed ID: 36622238
[TBL] [Abstract][Full Text] [Related]
8. Biochemical Activity of Vaborbactam.
Tsivkovski R; Lomovskaya O
Antimicrob Agents Chemother; 2020 Jan; 64(2):. PubMed ID: 31712199
[TBL] [Abstract][Full Text] [Related]
9. Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations.
Zhanel GG; Lawrence CK; Adam H; Schweizer F; Zelenitsky S; Zhanel M; Lagacé-Wiens PRS; Walkty A; Denisuik A; Golden A; Gin AS; Hoban DJ; Lynch JP; Karlowsky JA
Drugs; 2018 Jan; 78(1):65-98. PubMed ID: 29230684
[TBL] [Abstract][Full Text] [Related]
10. Meropenem-Vaborbactam Activity against Carbapenem-Resistant
Castanheira M; Doyle TB; Kantro V; Mendes RE; Shortridge D
Antimicrob Agents Chemother; 2020 Jan; 64(2):. PubMed ID: 31712207
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics/Pharmacodynamics of Vaborbactam, a Novel Beta-Lactamase Inhibitor, in Combination with Meropenem.
Griffith DC; Sabet M; Tarazi Z; Lomovskaya O; Dudley MN
Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30397063
[TBL] [Abstract][Full Text] [Related]
12. In vitro evaluation of meropenem-vaborbactam against clinical CRE isolates at a tertiary care center with low KPC-mediated carbapenem resistance.
Kinn PM; Chen DJ; Gihring TM; Schulz LT; Fox BC; McCreary EK; Lepak AJ
Diagn Microbiol Infect Dis; 2019 Mar; 93(3):258-260. PubMed ID: 30344065
[TBL] [Abstract][Full Text] [Related]
13. Meropenem-Vaborbactam Tested against Contemporary Gram-Negative Isolates Collected Worldwide during 2014, Including Carbapenem-Resistant, KPC-Producing, Multidrug-Resistant, and Extensively Drug-Resistant Enterobacteriaceae.
Castanheira M; Huband MD; Mendes RE; Flamm RK
Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28652234
[TBL] [Abstract][Full Text] [Related]
14. Meropenem-Vaborbactam Resistance Selection, Resistance Prevention, and Molecular Mechanisms in Mutants of KPC-Producing Klebsiella pneumoniae.
Sun D; Rubio-Aparicio D; Nelson K; Dudley MN; Lomovskaya O
Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 29038260
[TBL] [Abstract][Full Text] [Related]
15. Potency of Meropenem-Vaborbactam in Lung Surfactant.
Rubio-Aparicio D; Loutit J; Dudley M; Lomovskaya O
Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29038266
[TBL] [Abstract][Full Text] [Related]
16. Activity of ceftazidime/avibactam, meropenem/vaborbactam and imipenem/relebactam against carbapenemase-negative carbapenem-resistant Enterobacterales isolates from US hospitals.
Castanheira M; Doyle TB; Deshpande LM; Mendes RE; Sader HS
Int J Antimicrob Agents; 2021 Nov; 58(5):106439. PubMed ID: 34547421
[TBL] [Abstract][Full Text] [Related]
17. Meropenem/Vaborbactam: A Review in Complicated Urinary Tract Infections.
Dhillon S
Drugs; 2018 Aug; 78(12):1259-1270. PubMed ID: 30128699
[TBL] [Abstract][Full Text] [Related]
18. Activity of Meropenem Combined with RPX7009, a Novel β-Lactamase Inhibitor, against Gram-Negative Clinical Isolates in New York City.
Lapuebla A; Abdallah M; Olafisoye O; Cortes C; Urban C; Quale J; Landman D
Antimicrob Agents Chemother; 2015 Aug; 59(8):4856-60. PubMed ID: 26033723
[TBL] [Abstract][Full Text] [Related]
19. In vitro comparative activity of the new beta-lactamase inhibitor taniborbactam with cefepime or meropenem against Klebsiella pneumoniae and cefepime against Pseudomonas aeruginosa metallo-beta-lactamase-producing clinical isolates.
Meletiadis J; Paranos P; Georgiou PC; Vourli S; Antonopoulou S; Michelaki A; Vagiakou E; Pournaras S
Int J Antimicrob Agents; 2021 Nov; 58(5):106440. PubMed ID: 34551356
[TBL] [Abstract][Full Text] [Related]
20. Activity of novel β-lactam/β-lactamase inhibitor combinations against serine carbapenemase-producing carbapenem-resistant Pseudomonas aeruginosa.
Lee SY; Gill CM; Nicolau DP;
J Antimicrob Chemother; 2023 Dec; 78(12):2795-2800. PubMed ID: 37840005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
